ASCO 2026: Allogene announced a CEO succession plan late last week. The two leaders behind it discuss why now is the right time, and update us on the progress of the company's programs

8 hours ago
1 min read

Current CEO David Chang describes why now was the right time to pass the baton to Zach Roberts, and why they are both excited about the company's 1L large B-cell lymphoma program, and learnings on why they believe using a combo approach of CD19 and CD70 is an effective way to go about allogeneic therapy in the future.

https://vimeo.com/1197173517

Recent Posts

See All

$ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart$

ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart

ASCO 2026: BeOne Medicines presented at this year's meeting long-term data on Brukinsa in CLL and combo data with the company's Bcl-2. Chairman & CEO John V. Oyler discusses that and new modalities

ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck

ASCO 2026: Allogene announced a CEO succession plan late last week. The two leaders behind it discuss why now is the right time, and update us on the progress of the company's programs

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight